Biology:CDK19

From HandWiki

Cyclin-dependent kinase 19 is an enzyme that in humans is encoded by the CDK19 gene.[1][2][3]

Inhibitors

The natural product cortistatin A is a potent and selective inhibitor of CDK8 and CDK19.[4]

Romaciclib is a dual CDK8 and CDK19 inhibitor which is being developed for the treatment of acute myeloid leukaemia (AML).[5][6][7]

References

  1. ↑ "Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer". Oncogene 37 (35): 4792–4808. August 2018. doi:10.1038/s41388-018-0316-y. PMID 29780169. 
  2. ↑ "Regulatory functions of the Mediator kinases CDK8 and CDK19". Transcription 10 (2): 76–90. April 2019. doi:10.1080/21541264.2018.1556915. PMID 30585107. 
  3. ↑ "Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules". Frontiers in Cell and Developmental Biology 6. 2018. doi:10.3389/fcell.2018.00171. PMID 30693281. 
  4. ↑ "Mediator kinase inhibition further activates super-enhancer-associated genes in AML". Nature 526 (7572): 273–6. Oct 2015. doi:10.1038/nature14904. PMID 26416749. Bibcode: 2015Natur.526..273P. 
  5. ↑ "Romaciclib - Ryvu Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800035316. 
  6. ↑ "Clinical development of a CDK8/19 kinase inhibitor for acute myeloid leukemia". Expert Opinion on Investigational Drugs 35 (4): 253–256. April 2026. doi:10.1080/13543784.2026.2656430. PMID 41931045. 
  7. ↑ Pakulska U, Obacz M, Woźnicki J, Wiklik K, Chakraborty S, Micek M, Mohanty V, Coelho D, Adamczyk E, Gołas A, Moszyńska A, Zhang H, Cybulska-Lubak M, Kaniuga E, Sandowska-Markiewicz Z, Konopleva M, Mikula M, Juszczyński P, Shastri A, Baran N, Rzymski T, Mazan M (January 2026). "Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy". bioRxiv 10.64898/2025.12.16.693978. {{cite bioRxiv}}: Check |biorxiv= value (help)